TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of British Columbia
Sponsor:
Collaborator:
British Columbia Cancer Agency
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT01549457
First received: March 6, 2012
Last updated: August 7, 2014
Last verified: August 2014
  Purpose

This study will examine the impact of use of mobile phones and text messaging on adherence to treatment for patients with latent TB infection. Half (50%) of the 350 anticipated study participants will receive weekly text messages inquiring on their health status in relation to their prescribed treatment, while the other half (50%) will not receive weekly text messages at all. Medical adherence will be assessed by monthly blood-work, clinic visits and by interviewing patients at each of these visits.

The investigators hypothesis is that enhanced communication with a health care provider, via a structured cell phone SMS text messaging based program (WelTel), will result in a 15% improvement in the proportion of patients who successfully complete their LTBI treatment regimens.


Condition Intervention Phase
Latent Tuberculosis Infection
Other: Cell phone text messages
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: The Effect of Weekly Text-message Communication on Treatment Completion Among Patients With Latent Tuberculosis Infection: a Randomised Controlled Trial (WelTel LTBI)

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Successful completion of LTBI treatment regimens. [ Time Frame: 4 or 9 months ] [ Designated as safety issue: No ]
    Successful treatment completion is defined as taking at least 80% of the doses of INH prescribed within 12 months.


Estimated Enrollment: 350
Study Start Date: April 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Non-intervention
Participants will only receive standard of care
Experimental: Cell phone intervention arm
Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH) without weekly SMS text messages via mobile phone.
Other: Cell phone text messages
Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.

Detailed Description:
  1. Purpose

    The purpose of this study is to compare the proportion of patients who are adherent to their TB medications among those receiving weekly text messages plus standard of care and those who receive standard of care only.

  2. Justification:

    Previous research has shown that weekly text messages from a health care provider increases medication adherence for HIV patients. The investigators would like to determine if a similar effect in terms of adherence can be seen in patients receiving medication for latent tuberculosis infection

  3. Objectives

Primary Objective:

1) To compare successful treatment completion rates for patients treated with 9 months of INH between those receiving weekly SMS text messages via mobile phone plus standard of care to those receiving standard care. The standard of care at the TB clinics for all LTBI patients includes provision of a 30 day supply of medications - isoniazid 300mg daily for 9 months - at a time, monthly blood-work and monthly clinic visits. Successful treatment completion is defined as taking at least 80% of the doses of INH prescribed within 12 months.

Secondary Objectives:

  1. To compare the proportion of prescribed doses taken on schedule (daily adherence) prior to medication discontinuation or interruption on medical advice between those receiving weekly SMS text messages via mobile phone to those receiving standard care;
  2. To measure patient satisfaction with the SMS intervention using a provider administered questionnaire including a series of Likert questions.

4) Research Method

This study is a prospective open-label multicentre randomized controlled trial of a clinical intervention. It is estimated that 486 study participants will be required to have 80% power to detect a 15% difference in adherence at a .05 level of significance. In addition to recruiting English-speaking participants, the investigators will also be recruiting participants that have Chinese and Punjabi as their first language.

Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH) without weekly SMS text messages via mobile phone.

The clinicians, pharmacists and researchers involved in evaluating compliance will not be blinded to the allocation of the intervention and control groups, as they will be required to review patients charts periodically, respond to patients text messages when they are experiencing difficulty in taking medications or side effects, as well as to ensure the successful operation of the SMS technology platform.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Are initiating treatment for latent TB infection;
  2. Are over the age of 18 years old;
  3. Own a mobile phone or share access mobile phone access with a household member who consents to participate; AND
  4. Demonstrate sufficient ability to communicate via text messaging in English or have a family member or friend that is able to provide translation and assistance with text messaging for the duration of the study

Exclusion Criteria:

  1. Individuals under the age of 18;
  2. Unable to adequately send and receive text messages for any reason OR
  3. Enrolled in another clinical trial that may assess or influence treatment adherence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01549457

Contacts
Contact: Dr. Richard Lester, MD (604) 707-5606 richard.lester@bccdc.ca
Contact: Kirsten Smillie kirsten.smillie@bccdc.ca

Locations
Canada, British Columbia
New Westminster TB Control Clinic Recruiting
New Westminster, British Columbia, Canada
Contact: Dr. Richard Lester, MD    (604) 707-5606    richard.lester@bccdc.ca   
Vancouver TB Control Clinic (VTC), Recruiting
Vancouver, British Columbia, Canada
Contact: Dr. Richard Lester, MD       richard.lester@bccdc.ca   
Vancouver Downtown TB Control Clinic Recruiting
Vancouver, British Columbia, Canada
Contact: Dr. Richard Lester, MD    (604) 707-5606    richard.lester@bccdc.ca   
Sponsors and Collaborators
University of British Columbia
British Columbia Cancer Agency
Investigators
Principal Investigator: Dr. Richard Lester, MD BC Centre for Disease Control
  More Information

No publications provided

Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT01549457     History of Changes
Other Study ID Numbers: H11-02216
Study First Received: March 6, 2012
Last Updated: August 7, 2014
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
latent tuberculosis
text message interventions
medication adherence

Additional relevant MeSH terms:
Infection
Communicable Diseases
Tuberculosis
Latent Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on October 16, 2014